An interventional study of Standard care and PhysioMem PM 100 4G ambulatory monitoring system in Severe Aortic Valve Stenosis and Cardiovascular Diseases, sponsored by Hospital Universitari Vall d'Hebron Research Institute. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.
Sponsored by Hospital Universitari Vall d'Hebron Research Institute · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Aortic Valve Stenosis with a site in Spain — 25 open to participants now, 32 under way, 1 of them phase 3. Aortic Valve Stenosis · Spain.
Among the 83 studies in Aortic Valve Stenosis with a site in Spain, this one is the 30th largest by planned enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2026, is one of 26 with no phase, reaches primary completion later than 23 of the 31 other live ones, and was the 80th registered.
1,026 studies on the registry are indexed under Aortic Valve Stenosis; 294 are open to participants now.
Browse Aortic Valve Stenosis studies →25 of the 83 studies in Aortic Valve Stenosis with a site in Spain are open now. Recruiting first, the newest first:
Fundación EPIC · Sites in Spain
Ages 18+
Biosensors Europe SA · Sites in Spain
Ages 18+
Ceric Sàrl · Sites in Spain, Austria, Estonia and 11 more countries
Ages 65–75
Shanghai MicroPort CardioFlow Medtech Co., Ltd. · Sites in Spain, Ireland, Italy and 2 more countries
Ages 18+
Hospital Clinic of Barcelona · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 25 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 3 · Phase 4 7
First in 2006; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 126 across 554 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 209 across the 37 interventional studies, 373 across the 46 observational. Of the 42 that completed or were terminated, 9 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 83 have an industry lead sponsor. The 10 most frequent:
Hospital Universitari Vall d'Hebron Research Institute is the lead sponsor of 276 studies on the registry; 64 are open to participants now.
Hospital Universitari Vall d'Hebron Research Institute has 2 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Aortic Valve Stenosis with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05758909Fundación EPICEvaluation of the Viability and Safety of Early Discharge Protocol After TAVI Implantation | 2026-12-01 |
| NCT06833762Hospital Clinic of BarcelonaClinical and CPET Parameters That Predict Improvement in Functional Capacity After TAVI | 2027-06 |
| NCT05283356Fundacin Biomedica Galicia SurSingle Antiplatelet Treatment With Ticagrelor or Aspirin After Transcatheter Aortic Valve Implantation | 2027-06-30 |
| NCT06008080Abbott Medical DevicesPost-Market Clinical Follow Up Study With Navitor Valve | 2027-07 |
| NCT06049654Fundación EPICComparison of Allegra vs Sapien Transcatheter Aortic Valves in Valve-In-Valve Indication | 2027-11-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 83 studies in Aortic Valve Stenosis with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study to evaluate the efficacy and safety of a non-invasive electrocardiographic monitoring strategy associated with early discharge in patients with conduction disorder after transfemoral TAVI implantation, and its potential benefits compared to standard care.
Study to evaluate the efficacy and safety of a non-invasive electrocardiographic monitoring strategy associated with early discharge in patients with conduction disorder after transfemoral TAVI implantation, and its potential benefits compared to standard care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All inclusion criteria must be met
Exclusion Criteria:
No exclusion criteria must be met
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will be discharged from the hospital 24 hours post-TAVI with PhysioMem PM 100 4G ambulatory monitoring system.
Device: PhysioMem PM 100 4G ambulatory monitoring system
Patients will be discharged from the hospital according standard care
Behavioral: Standard care
Patients discharged according to standard care
Patients discharged with PhysioMem PM 100 4G ambulatory monitoring system
Composite of all-cause death and rehospitalization for any reason
Proportion of patients with: * All cause of death * Rehospitalization for any reason
Time frame: 30 days
Clinically relevant arrhythmic event requiring a change in therapy
Proportion of patients with clinically relevant arrhythmic event requiring a change in therapy, defined as the occurrence of any of the following: * Cardiac conduction disorders * Clinically relevant tachyarrhythmias
Time frame: 30 days
All-cause death
Incidence of all-cause death
Time frame: 30 days
All-cause death
Incidence of all-cause death
Time frame: 12 months
Unscheduled hospital readmission for any reason
Incidence of unscheduled hospital readmission for any reason
Time frame: 30 days
Unscheduled hospital readmission for any reason
Incidence of unscheduled hospital readmission for any reason
Time frame: 12 months
Cardiovascular death
Incidence of cardiovascular death
Time frame: 30 days
Cardiovascular death
Incidence of cardiovascular death
Time frame: 12 months
Hospital readmission due to cardiovascular cause
Incidence of Hospital readmission due to cardiovascular cause
Time frame: 30 days
Hospital readmission due to cardiovascular cause
Incidence of Hospital readmission due to cardiovascular cause
Time frame: 12 months
Implantation of a permanent pacemaker
Incidence of Implantation of a permanent pacemaker
Time frame: 30 days
Implantation of a permanent pacemaker
Incidence of Implantation of a permanent pacemaker
Time frame: 12 months
High-degree atrioventricular block (II or III)
Incidence of High-degree atrioventricular block (II or III)
Time frame: 30 days
De novo or recurrent atrial fibrillation requiring a change in therapy
Incidence of De novo or recurrent atrial fibrillation requiring a change in therapy
Time frame: 30 days
Time to pacemaker implantation or therapeutic change due to arrhythmia
Incidence of Time to pacemaker implantation or therapeutic change due to arrhythmia
Time frame: 30 days
Time to pacemaker implantation or therapeutic change due to arrhythmia
Incidence of Time to pacemaker implantation or therapeutic change due to arrhythmia
Time frame: 12 months
Resolution vs persistence of conduction disorders
Incidence of Resolution vs persistence of conduction disorders detected in the first 72 hours after TAVI implantation
Time frame: 72 hours
QRS evolution: transient, persistent, or normalisation
Incidence of QRS evolution: transient, persistent, or normalisation
Time frame: 30 days
Remote monitoring
Percentage of time monitored correctly
Time frame: 30 days
hospital length to of stay from TAVI to discharge
Duration of hospitalization post-TAVI procedure
Time frame: At discharge
Direct cost associated with stay and readmissions
Evaluation of Direct cost associated with hospital stay and readmissions
Time frame: 12 Months
Quality of life assessed using Kansas City Cardiomyopathy Questionnaire (KCCQ)
Quality of life assessed using (KCCQ)assessed using Kansas City Cardiomyopathy Questionnaire (KCCQ). The KCCQ is a 23-item questionnaire developed to assess HRQoL (Health-Related Quality of Life) in patients with congestive heart failure. The KCCQ consists of five domains: physical limitation, symptoms (frequency, severity, and recent change over time), QoL (Quality of Life), social interference, and self-efficacy. The total score ranges from 0 to 100, and higher scores reflect better health status.
Time frame: 30 days
Quality of life assessed using Kansas City Cardiomyopathy Questionnaire (KCCQ)
Quality of life assessed using (KCCQ)assessed using Kansas City Cardiomyopathy Questionnaire (KCCQ). The KCCQ is a 23-item questionnaire developed to assess HRQoL (Health-Related Quality of Life) in patients with congestive heart failure. The KCCQ consists of five domains: physical limitation, symptoms (frequency, severity, and recent change over time), QoL (Quality of Life), social interference, and self-efficacy. The total score ranges from 0 to 100, and higher scores reflect better health status.
Time frame: 12 Months
Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 23 months after the start.
Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 23 months is below that.
Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Universitari Vall d'Hebron Research Institute →